Technical Analysis for TROV - TrovaGene, Inc.

Grade Last Price % Change Price Change
grade F 3.07 -0.32% -0.01
TROV closed down 0.32 percent on Monday, May 20, 2019, on 8 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical TROV trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
180 Bearish Setup Bearish Swing Setup -0.32%
Narrow Range Bar Range Contraction -0.32%
Outside Day Range Expansion -0.32%
Oversold Stochastic Weakness -0.32%
Narrow Range Bar Range Contraction -2.85%
NR7 Range Contraction -2.85%
NR7-2 Range Contraction -2.85%

Older signals for TROV ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Trovagene Inc., a development stage molecular diagnostic company, focuses on the development and commercialization of proprietary diagnostic technologies for use in patient/disease screening and monitoring in various medical disciplines. The company's urine-based testing platform facilitates to enhance the management of cancer care and women's healthcare. Its proprietary urine-based molecular diagnostic tests are used to detect transrenal DNA and RNA that are cell-free nucleic acids found in urine. The company's technology is applied in various testing, such as tumor detection and monitoring, prenatal genetic testing, infectious diseases, tissue transplantation, and forensic identification, as well as for patient selection in clinical trials. In addition, it owns rights to nucleophosmin-1, an informative biomarker for acute myeloid leukemia and mutations in the SF3B1 gene that are to be associated with chemotherapy response in chronic lymphocytic leukemia patients. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene Inc. in January 2010. Trovagene Inc. was founded in 1999 and is headquartered in San Diego, California.
Medicine Biotechnology Cancer Healthcare Clinical Medicine Infectious Diseases Oncology Chemotherapy Tumor Acute Myeloid Leukemia Diagnostic Tests Leukemia Transplantation Chronic Lymphocytic Leukemia Cancer Care Biomarkers
Is TROV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 3 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 20.232
52 Week Low 2.5362
Average Volume 817,842
200-Day Moving Average 4.1412
50-Day Moving Average 3.6662
20-Day Moving Average 3.3585
10-Day Moving Average 3.17
Average True Range 0.2518
ADX 28.69
+DI 24.6233
-DI 18.4524
Chandelier Exit (Long, 3 ATRs ) 3.4446
Chandelier Exit (Short, 3 ATRs ) 3.7954
Upper Bollinger Band 3.7923
Lower Bollinger Band 2.9247
Percent B (%b) 0.17
BandWidth 25.832961
MACD Line -0.1511
MACD Signal Line -0.1299
MACD Histogram -0.0212
Fundamentals Value
Market Cap 114.41 Million
Num Shares 37.3 Million
EPS -1.25
Price-to-Earnings (P/E) Ratio -2.45
Price-to-Sales 76.85
Price-to-Book 6.46
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.19
Resistance 3 (R3) 3.20 3.17 3.17
Resistance 2 (R2) 3.17 3.14 3.17 3.16
Resistance 1 (R1) 3.12 3.12 3.11 3.11 3.16
Pivot Point 3.09 3.09 3.08 3.09 3.09
Support 1 (S1) 3.04 3.06 3.03 3.03 2.98
Support 2 (S2) 3.01 3.04 3.01 2.98
Support 3 (S3) 2.96 3.01 2.97
Support 4 (S4) 2.95